| TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis C Conrad, J Di Domizio, A Mylonas, C Belkhodja, O Demaria, AA Navarini, ... Nature communications 9 (1), 25, 2018 | 229 | 2018 |
| Targeting CD8+ T cells prevents psoriasis development P Di Meglio, F Villanova, AA Navarini, A Mylonas, I Tosi, FO Nestle, ... Journal of Allergy and Clinical Immunology 138 (1), 274-276. e6, 2016 | 141 | 2016 |
| Psoriasis: classical vs. paradoxical. The Yin-Yang of TNF and type I interferon A Mylonas, C Conrad Frontiers in immunology 9, 2746, 2018 | 127 | 2018 |
| Interleukin 23–helper T cell 17 axis as a treatment target for pityriasis rubra pilaris L Feldmeyer, A Mylonas, O Demaria, A Mennella, N Yawalkar, E Laffitte, ... JAMA dermatology 153 (4), 304-308, 2017 | 107 | 2017 |
| IL-17E (IL-25) enhances innate immune responses during skin inflammation L Senra, A Mylonas, RD Kavanagh, PG Fallon, C Conrad, ... Journal of Investigative Dermatology 139 (8), 1732-1742. e17, 2019 | 51 | 2019 |
| Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis R Schwotzer, AJ Flammer, S Gerull, T Pabst, P Arosio, M Averaimo, ... Swiss medical weekly 150, w20364, 2020 | 15 | 2020 |
| Paradoxical psoriasis induced by anti-TNF-a clinical challenge A Nidegger, A Mylonas, C Conrad Revue medicale suisse 15 (644), 668-671, 2019 | 13 | 2019 |
| Type I interferons link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea A Mylonas, H Hawerkamp, Y Wang, O Demaria, S Meller, B Homey, ... | 1 | 2022 |
| Psoriasis paradoxal induit par anti-TNF un challenge en clinique. A Nidegger, A Mylonas, C Conrad Rev Med Suisse, 668-671, 2019 | | 2019 |
| SIMILAR, YET DISTINCT, PATHOGENIC PATHWAYS OF PLASMACYTOID DENDRITIC CELL-DERIVED TYPE-IINTERFERON-DRIVEN CUTANEOUS INFLAMMATION IN ROSACEA AND PARADOXICAL PSORIASIS A Mylonas Université de Lausanne, Faculté de biologie et médecine, 2017 | | 2017 |
| Map4k3 and the Posttranscriptional Control of Gene Expression: A closer look at the MAP kinase control over the tumour promoting mTOR pathway A Mylonas University of Leicester, 2013 | | 2013 |
